Metrics to compare | 310210 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship310210PeersSector | |
|---|---|---|---|---|
P/E Ratio | −27.6x | −19.9x | −0.2x | |
PEG Ratio | 0.46 | −0.17 | 0.00 | |
Price/Book | 27.6x | 2.7x | 2.6x | |
Price / LTM Sales | 458.3x | 24.0x | 2.6x | |
Upside (Analyst Target) | 223.2% | 123.9% | 76.9% | |
Fair Value Upside | Unlock | 11.7% | 14.9% | Unlock |
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.